These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12857356)

  • 1. Physicians' ability to predict the risk of coronary heart disease.
    Pignone M; Phillips CJ; Elasy TA; Fernandez A
    BMC Health Serv Res; 2003 Jul; 3(1):13. PubMed ID: 12857356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A survey of physicians show a one-third reduction in harmful outcomes to be a clinically important difference for statin therapy.
    Li KK; Holbrook AM; Thabane L; Teo KK
    J Clin Epidemiol; 2012 Sep; 65(9):954-61. PubMed ID: 22742918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attitude changes of general practitioners towards lowering LDL cholesterol.
    Strandberg TE; Pitkänen A; Larjo P; Hirvonen P; Kohvakka A
    J Cardiovasc Risk; 1998 Feb; 5(1):43-6. PubMed ID: 9816555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential use of 10-year and lifetime coronary risk information for preventive cardiology prescribing decisions: a primary care physician survey.
    Persell SD; Zei C; Cameron KA; Zielinski M; Lloyd-Jones DM
    Arch Intern Med; 2010 Mar; 170(5):470-7. PubMed ID: 20212185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
    Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
    Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol: precursor to many lipid disorders.
    Jones PH
    Am J Manag Care; 2001 Aug; 7(9 Suppl):S289-98. PubMed ID: 11517815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study.
    Jacobson TA; Gutkin SW; Harper CR
    Curr Med Res Opin; 2006 Jun; 22(6):1065-73. PubMed ID: 16846539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary risk estimates and decisions on lipid-lowering treatment in primary prevention: comparison between general practitioners, internists, and cardiologists.
    Vancheri F; Strender LE; Montgomery H; Skånér Y; Backlund LG
    Eur J Intern Med; 2009 Oct; 20(6):601-6. PubMed ID: 19782921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol complacency in Australia: time to revisit the basics of cardiovascular disease prevention.
    Carrington MJ; Retegan C; Johnston CI; Jennings GL; Stewart S
    J Clin Nurs; 2009 Mar; 18(5):678-86. PubMed ID: 19077020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emergence of triglycerides as a significant independent risk factor in coronary artery disease.
    Assmann G; Schulte H; Funke H; von Eckardstein A
    Eur Heart J; 1998 Oct; 19 Suppl M():M8-14. PubMed ID: 9821011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y
    J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.
    Waters DD; Brotons C; Chiang CW; Ferrières J; Foody J; Jukema JW; Santos RD; Verdejo J; Messig M; McPherson R; Seung KB; Tarasenko L;
    Circulation; 2009 Jul; 120(1):28-34. PubMed ID: 19546386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.